	US 12,264,187 B2
	Compositions and methods for targeted therapeutic delivery to bone
Luis Alvarez, Lexington, MA (US); David Stewart, Monrovia, MD (US); Hyeon Park, Clarksburg, MD (US); and Todd Heil, Mt. Airy, MD (US)
Assigned to Theradaptive, Inc., Frederick, MD (US)
Filed by Theradaptive, Inc., Frederick, MD (US)
Filed on Oct. 14, 2022, as Appl. No. 18/046,810.
Application 18/046,810 is a continuation of application No. PCT/US2021/027230, filed on Apr. 14, 2021.
Claims priority of provisional application 63/010,639, filed on Apr. 15, 2020.
Prior Publication US 2023/0235002 A1, Jul. 27, 2023
Int. Cl. A61K 38/18 (2006.01); A61P 19/00 (2006.01); C07K 14/475 (2006.01); C07K 14/51 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01)

CPC C07K 14/51 (2013.01) [A61K 38/18 (2013.01); A61P 19/00 (2018.01); C07K 14/475 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01)]

19 Claims

1. A polypeptide composition comprising: a targeting polypeptide comprising a sequence at least 95% identical to SEQ ID NO: 22 (LLADTTHHRPWT VIGESTHHRPWS IIGESSHHKPFT GLGDTTHHRPWG ILAESTHHKPWT), connected to a therapeutic polypeptide comprising a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 32, 55, 58, 59, 60, 61, 62, 64, 65 and 71, wherein the targeting polypeptide binds to calcium phosphate.